Research programme: cystic fibrosis therapy - Inologic

Drug Profile

Research programme: cystic fibrosis therapy - Inologic

Alternative Names: Cystic fibrosis therapy research programme - Inologic; INO 4995

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inologic
  • Class Inositol phosphates
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
  • 03 Dec 2003 INO 4995 has received orphan drug status for cystic fibrosis in USA
  • 20 Oct 2003 Inologic has selected a lead compound, INO 4995, for clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top